Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corpor...(accounting firm on the Company's financi...),Health

2009 Goals and Objectives

The Company expects to make the following progress in picoplatin's clinical development and potential commercialization:

• Complete enrollment in the pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial as a second-line treatment for small cell lung cancer (SCLC);

• Report the Phase 3 SPEAR trial data, and initiate submission of a New Drug Application with the U.S. Food and Drug Administration for picoplatin as a second-line treatment for SCLC (targeting approval and commercialization in 2010);

• Present additional efficacy and safety data from the ongoing Phase 2 trials of picoplatin in colorectal and prostate cancers at medical conferences this year; and

• Present clinical data from Phase 1 trials of intravenous picoplatin in colorectal cancer and oral picoplatin in solid tumors this year.

Conference Call Details

Poniard's management team will host a live conference call and Web cast today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. To participate by telephone, please dial 877-719-9791 from the U.S. or 719-325-4811 for international callers. The Web cast can be accessed on the "Events" page of the "News & Events" section of the Company's Web site at http://www.poniard.com. A replay of the Web cast will be available on the Company's Web site for 10 days.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical comp
'/>"/>